Oostenbrink J - Search Results

1

Predictors for achieving protein and energy requirements in undernourished hospital patients.

Leistra E, Willeboordse F, van Bokhorst-de van der Schueren MA, Visser M, Weijs PJ, Haans-van den Oord A, Oostenbrink J, Evers AM, Kruizenga HM. Leistra E, et al. Among authors: oostenbrink j. Clin Nutr. 2011 Aug;30(4):484-9. doi: 10.1016/j.clnu.2011.01.008. Epub 2011 Mar 3. Clin Nutr. 2011. PMID: 21376433

2

Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?

Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Rutten-van Mölken MP, et al. Among authors: oostenbrink jb. Chest. 2006 Oct;130(4):1117-28. doi: 10.1378/chest.130.4.1117. Chest. 2006. PMID: 17035446 Clinical Trial.

3

Resource use and risk factors in high-cost exacerbations of COPD.

Oostenbrink JB, Rutten-van Mölken MP. Oostenbrink JB, et al. Respir Med. 2004 Sep;98(9):883-91. doi: 10.1016/j.rmed.2004.02.013. Respir Med. 2004. PMID: 15338802 Free article.

4

Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Oostenbrink JB, Al MJ, Rutten-van Mölken MP. Oostenbrink JB, et al. Pharmacoeconomics. 2003;21(15):1103-12. doi: 10.2165/00019053-200321150-00004. Pharmacoeconomics. 2003. PMID: 14596629 Clinical Trial.

5

Costs of nine common mental disorders: implications for curative and preventive psychiatry.

Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A. Smit F, et al. Among authors: oostenbrink j. J Ment Health Policy Econ. 2006 Dec;9(4):193-200. J Ment Health Policy Econ. 2006. PMID: 17200596

6

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM. Oostenbrink JB, et al. Value Health. 2005 Jan-Feb;8(1):32-46. doi: 10.1111/j.1524-4733.2005.03086.x. Value Health. 2005. PMID: 15841892 Free article.

7

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Rutten-van Mölken MP, et al. Among authors: oostenbrink jb. Eur J Health Econ. 2007 Jun;8(2):123-35. doi: 10.1007/s10198-007-0039-4. Epub 2007 Mar 17. Eur J Health Econ. 2007. PMID: 17370096 Free PMC article. Clinical Trial.

8

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.

Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MP. Oostenbrink JB, et al. Value Health. 2008 Dec;11(7):1070-80. doi: 10.1111/j.1524-4733.2008.00389.x. Value Health. 2008. PMID: 19602213 Free article.

9

Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.

Oostenbrink JB, Rutten-van Mölken MP, Sluyter-Opdenoordt TS. Oostenbrink JB, et al. J Glaucoma. 2001 Jun;10(3):184-91. doi: 10.1097/00061198-200106000-00007. J Glaucoma. 2001. PMID: 11442180

10

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

Oostenbrink JB, Rutten-van Mölken MP, Al MJ, Van Noord JA, Vincken W. Oostenbrink JB, et al. Eur Respir J. 2004 Feb;23(2):241-9. doi: 10.1183/09031936.03.00083703. Eur Respir J. 2004. PMID: 14979498 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters